Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENSET - GENXY -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (9)	7/11/1999 8:48:00 PM
From: Walkingshadow	Respond to of 200

Stuart--- Thanks for the abstract. The first thought that comes to mind is that the activity and/or expression of this receptor would likely be modulated at several levels from varying sources of input. The receptor may be fairly easily up- or downgradeable. Homeostatic regulatory mechanisms tend to be this way, and the control systems may exhibit considerable redundancy. The reason I bring this up is that this could render efforts to stimulate or inhibit this pathway not as straightforward as one may hope, particularly in the intact animal---the control systems will tend to work against you, and may do so very effectively. This work was carried out in vitro with cell culture systems. Not to rain on the parade, even though it seems so; this strategy bears watching..... Of course, from GENXY's standpoint, these considerations may not matter so much, if they can negotiate profitable licensing partnerships. Thanks again, Walkingshadow